Last updated: 11/07/2018 15:20:12
Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)
EudraCT ID
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months Administration of SB-683699 in Subjects with Relapsing-Remitting Multiple Sclerosis
Trial description: SB-683699 is an oral medication that is thought to reduce the number of active white blood cells entering the brain; these white blood cells are part of the disease process for MS. This study will look at whether different doses of SB-683699 are effective and safe in patients with relapsing remitting MS.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Allocation:
Randomized
Primary outcomes:
Cumulative number of new gadolinium-enhancing lesions on monthly Magnetic resonance imaging (MRI) scans during the Treatment Phase (Week 4 to week 24).
Timeframe: Week 4, 8, 12,16, 20, 24, 28 and Week 32
Secondary outcomes:
Cumulative volume of new gadolinium-enhancing lesions on monthly MRI scans
Timeframe: Week 4, 8, 12,16, 20, 24, 28 and Week 32
Cumulative number of persistent gadolinium-enhancing lesions on monthly MRI scans
Timeframe: Week 4, 8, 12,16, 20, 24, 28 and Week 32
Cumulative number of total enhancing lesions on monthly MRI scans: the sum of new and persistent gadolinium-enhancing lesions
Timeframe: Week 4, 8, 12,16, 20, and Week 24
Number of new T1 hypointense lesions on MRI scans at week 12, week 24 and week 36
Timeframe: Week 12, 24 and Week 36
Number of new or newly enlarging T2 lesions on MRI scans to week 12, week 24 and week 36
Timeframe: Week 12, Week 24 and Week 36
Change from Baseline in Cumulative Volume of New or Newly Enlarging T2 Lesions on MRI Scans to Week 24
Timeframe: At Week 24
Relapses occurring during the On-treatment phase
Timeframe: up to Week 24
Number of new active lesions at Week 24
Timeframe: At week 24
Number of participants with Change from baseline in Expanded Disability Status Scale (EDSS) scores
Timeframe: Baseline (Week 0) and 24 weeks
Change from baseline in Multiple Sclerosis Functional Composite (MSFC)scores
Timeframe: Baseline (Week 0) and Week 24
Interventions:
Other: Placebo
Drug: Firategrast 150 mg
Drug: Firategrast 300 mg
Enrollment:
343
Observational study model:
Not applicable
Primary completion date:
2009-24-08
Time perspective:
Not applicable
Clinical publications:
David H. Miller, M.D.; Thomas Weber; Richard Grove, Claire Wardell; Joseph Horrigan, MD; Ole Graff, Gillian Atkinson; Pinky Dua; Tarek Yousry, MD; David MacManus; Xavier Montalban, MD. Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial . Lancet Neurol. 2012;11(2):131-139.
Medical condition
Multiple Sclerosis
Product
firategrast
Collaborators
Not applicable
Study date(s)
December 2006 to May 2010
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
18 - 65 years
Accepts healthy volunteers
No
- Written informed consent
- Males or females, aged 18 to 65, inclusive
- Subjects receiving corticosteroids within 4 weeks of Screening for treatment of MS. If non-systemic steroids are being used for other chronic inflammatory conditions, subjects may be included at the discretion of the investigator after discussion with the GSK medical monitor
- Use of an b-interferon product, glatiramer acetate or azathioprine within 3 months of Screening, or use of Mitoxantrone within 12 months of Screening. Subjects who have received other therapies affecting the immune system (such as intravenous immunoglobulin (IVIg), cyclophosphamide, plasmapheresis, or any other immunosuppressive or immunomodulatory treatment) in the past may be included on a case by case basis after discussion with the GSK medical monitor. None of these treatments will be allowed during this study
Inclusion and exclusion criteria
Inclusion criteria:
- Written informed consent
- Males or females, aged 18 to 65, inclusive
- A diagnosis of relapsing-remitting MS [Polman, 2005; McDonald, 2001] with dissemination in time and space
- EDSS of between 0 and 6.0 inclusive at the Screening visit
- Occurrence of at least two relapses in previous 24 months with at least one relapse or documented evidence of gadolinium-enhancement on MRI (prior to screening) in the previous 12 months. Subject must not have had a relapse within 4 weeks prior to Screening. In addition, subjects experiencing a relapse between Screen and Visit 3 will not be eligible to be randomized.
- A minimum of five T2 lesions on brain MRI at Visit 2 as determined by the central MRI analysis reader
- In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.
A female subject is eligible to enter the study if she is: •Of non-childbearing potential, i.e. women who: •have documented evidence of tubal ligation, bilateral oophorectomy or hysterectomy; or •are post-menopausal, defined as at least one year without menses in the absence of hormone replacement therapy. In questionable cases, menopausal status will be confirmed by oestradiol and FSH levels consistent with menopause according to local laboratory ranges. Oestrogen-containing hormone replacement therapies are not allowed during the study. •Of childbearing potential, has a negative urine pregnancy test at Screening, and agrees to the consistent and correct use of one of the methods of contraception listed below. Subjects will use this contraceptive method for at least one month prior to Screening and should continue to use the same contraceptive method throughout the study until at least 3 days after the last dose of investigational product. •Progesterone-only oral contraceptives or implants (inserted at least one month prior to Screening, but not beyond the third successive year following insertion). Oestrogen-containing contraceptives are not allowed during the study. •Intra-uterine device (IUD) inserted by a qualified clinician. The IUD must have published data showing that the highest expected failure rate is less than 1% per year. •Spermicide in conjunction with either a diaphragm, cervical cap or condom. Male partner sterilization (vasectomy) prior to female subject's entry into the study and is the sole partner for that female subject
Exclusion criteria:
- Subjects receiving corticosteroids within 4 weeks of Screening for treatment of MS. If non-systemic steroids are being used for other chronic inflammatory conditions, subjects may be included at the discretion of the investigator after discussion with the GSK medical monitor
- Use of an b-interferon product, glatiramer acetate or azathioprine within 3 months of Screening, or use of Mitoxantrone within 12 months of Screening. Subjects who have received other therapies affecting the immune system (such as intravenous immunoglobulin (IVIg), cyclophosphamide, plasmapheresis, or any other immunosuppressive or immunomodulatory treatment) in the past may be included on a case by case basis after discussion with the GSK medical monitor. None of these treatments will be allowed during this study
- Previous exposure to alemtuzumab, natalizumab or firategrast administration, bone marrow transplantation or whole body irradiation
- Subjects with a cardiac pacemaker or any other type of metal implant or with any other contraindication for MRI (including known allergy to gadolinium)
- Use of 4-aminopyridine, rosiglitazone, pioglitazone or any drug that is an inhibitor of or a substrate (with a low therapeutic index) for OATP at Screening.
- Subjects with clinically significant renal laboratory values: subjects with a calculated creatinine clearance <60ml/min (by Cockcroft and Gault) at Screening
- Subjects with local urinalysis findings of 1) proteinuria, defined as ≥1+ protein, on urine dipstick or 2) renal tubular cell casts or 3) ≥5 red blood cells / high power field will be excluded from the study if the result is still present on a repeat urinalysis during the screening period.
- Presence of clinically significant hepatic laboratory values: ALT, AST, GGT > 2.0- times the upper limit of normal (ULN); total bilirubin > 1.5 times the ULN at Screening
- CD4 count <500, CD4:CD8 <1.0 (if result still present on a repeat test during the screening period), JC viremia detected in plasma or white cells, idiopathic CD4/CD8 lymphopenia or secondary lymphopenia at Screening
- Any findings on the MRI of the brain at Visit 2 other than MS, except for benign findings that (in the opinion of the central MRI reading site and local site investigator) require no further evaluation or treatment and do not impact patient's neurological health (e.g., small arachnoid cysts, venous angiomas)
- Current or history of cancer, excluding localized non-melanoma skin cancer
- Uncontrolled or any active bacterial, viral, or fungal infection at Screening. Any previous serious infections should be discussed with the GSK medical monitor (e.g. opportunistic or atypical infections)
- History of tuberculosis (TB) or positive chest X-ray for TB at Screening (prior chest X-ray is acceptable if performed within previous 6 months)
- Known congenital or acquired immunodeficiency
- Any abnormality on 12-lead ECG at Screening which is clinically significant in the opinion of the investigator
- Subjects with positive hepatitis B surface antigen, hepatitis C antibody, or HIV tests at Screening
- Women who are lactating, pregnant (positive pregnancy test at Screening), or planning to become pregnant during the course of the study
- Recent history or suspicion of current drug abuse (including analgesic abuse) or alcohol abuse within the last 6 months prior to Screening
- Use of an investigational drug for condition other than MS within 30 days or five half‑lives (whichever is longer) preceding Screening. Prior use of an investigational drug for MS should be discussed with the GSK medical monitor
- Any concurrent illness, disability or clinically significant abnormality (including laboratory tests) that may affect the interpretation of clinical efficacy or safety data or prevent the subject from safely completing the assessments required by the protocol
Trial location(s)
Location
GSK Investigational Site
Bielefeld, Nordrhein-Westfalen, Germany, 33647
Status
Study Complete
Location
GSK Investigational Site
Woodville, South Australia, Australia, 5011
Status
Study Complete
Location
GSK Investigational Site
Newcastle-Upon-Tyne, United Kingdom, NE1 4LP
Status
Study Complete
Location
GSK Investigational Site
Gallarate, Lombardia, Italy, 21013
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Kogarah, New South Wales, Australia, 2217
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Dueren, Nordrhein-Westfalen, Germany, 52349
Status
Study Complete
Location
GSK Investigational Site
Hartshill, Stoke-on-Trent, United Kingdom, ST4 7LN
Status
Study Complete
Location
GSK Investigational Site
Rostock, Mecklenburg-Vorpommern, Germany, 18147
Status
Study Complete
Location
GSK Investigational Site
Neuburg / Donau, Bayern, Germany, 86633
Status
Study Complete
Location
GSK Investigational Site
Unterhaching, Bayern, Germany, 82008
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Greenfield Park, Québec, Canada, J4V 2J2
Status
Study Complete
Location
GSK Investigational Site
Camperdown, New South Wales, Australia, 2050
Status
Study Complete
Location
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45122
Status
Study Complete
Location
GSK Investigational Site
Koeln, Nordrhein-Westfalen, Germany, 51109
Status
Study Complete
Location
GSK Investigational Site
Bad Honnef, Nordrhein-Westfalen, Germany, 53604
Status
Study Complete
Location
GSK Investigational Site
Romford, Essex, United Kingdom, RM7 0AG
Status
Study Complete
Location
GSK Investigational Site
Ulm, Baden-Wuerttemberg, Germany, 89075
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Gosford, New South Wales, Australia, 2320
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30625
Status
Study Complete
Location
GSK Investigational Site
Koeln, Nordrhein-Westfalen, Germany, 50767
Status
Study Complete
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2009-24-08
Actual study completion date
2010-27-05
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website